Maha Radhakrishnan
Maha Radhakrishnan is an executive with experience in biopharmaceutical product development and commercialization. She joined Sofinnova in 2024 and currently serves on the boards of Claris Bio and City Therapeutics.
What Maha can write
Sofinnova Investments writes $10M to $30M checks, larger than 97% of firms in the atlas.
Bars: how many firms report each check band. Highlighted: Sofinnova Investments.Career
- Biogen · Chief Medical Officer2020-2024
- Dyne Therapeutics · Consultant to the CEO
- Cephalon2005-2006
- United Health Group2006-2008
- Bristol Myers Squibb2009-2013
- Biogen2013-2016
- Bioverativ Inc.2016-2018
- Sofinnova Investments · Executive PartnerNow
Investments named in public bios
Focus
Education
Also at Sofinnova Investments
Partners like Maha
At firms with a similar stage, sector and check size.
Alert me when Sofinnova Investments is active
One email when Maha's firm raises a fund, adds a partner or shows new activity.
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckQuestions
Who is Maha Radhakrishnan?
Maha Radhakrishnan is an executive with experience in biopharmaceutical product development and commercialization. She joined Sofinnova in 2024 and currently serves on the boards of Claris Bio and City Therapeutics.
How much does Maha Radhakrishnan invest?
Maha Radhakrishnan invests through Sofinnova Investments, which writes checks of $10M to $30M at series a, series b.
How do I pitch Maha Radhakrishnan?
Email [email protected], the firm's inbox for founders, and name Maha in the subject. A warm intro from a founder Sofinnova Investments backed works better.
What did Maha Radhakrishnan do before Sofinnova Investments?
Chief Medical Officer at Biogen; Consultant to the CEO at Dyne Therapeutics; Cephalon; United Health Group; Bristol Myers Squibb; Biogen; Bioverativ Inc..
Last updated 2026-10-15. Is this you? Ask for a correction.